What are the recommended non‑pharmacologic and pharmacologic treatments for insomnia in young adults (approximately 18‑40 years) compared with older adults (≥65 years)?

Treatment and Medication for Insomnia in Young Adults vs. Older Adults

Young Adults (18–40 years)

First-Line Treatment: Cognitive Behavioral Therapy for Insomnia (CBT-I)

All young adults with chronic insomnia should receive CBT-I as the initial intervention before any pharmacologic agent is prescribed. 1, 2

• CBT-I combines sleep restriction therapy (limiting time in bed to match actual sleep time), stimulus control (using the bedroom only for sleep and sex, leaving if unable to fall asleep within 20 minutes), cognitive restructuring of unhelpful beliefs about sleep, and relaxation techniques (progressive muscle relaxation, guided imagery, diaphragmatic breathing). 2, 3, 4, 5
• CBT-I can be delivered through individual therapy, group sessions, telephone-based programs, web-based modules, or self-help books—all formats demonstrate effectiveness. 2, 3
• The effects of CBT-I are sustained for up to 2 years after treatment completion, unlike medications which lose efficacy upon discontinuation. 2, 3
• Sleep hygiene education alone (stable bedtimes, avoiding caffeine/alcohol, comfortable bedroom environment) is insufficient as a standalone treatment and must be combined with other CBT-I components. 2, 4

Second-Line Treatment: Pharmacotherapy (Only After CBT-I Failure)

Pharmacotherapy should only be considered when CBT-I alone has been unsuccessful, using shared decision-making that discusses benefits, harms, and costs of short-term medication use. 1, 2

For Sleep-Onset Insomnia:

• Ramelteon 8 mg at bedtime is appropriate, with minimal adverse effects and no risk of dependence. 2, 3
• Short-acting Z-drugs (zolpidem 5–10 mg, zaleplon 5–10 mg) are alternatives for sleep-onset insomnia. 2, 6

For Sleep-Maintenance Insomnia:

• Suvorexant 10–20 mg improves sleep maintenance with mild side effects. 2, 6, 7
• Low-dose doxepin 3–6 mg is effective for sleep maintenance. 2, 6

For Combined Sleep-Onset and Maintenance Insomnia:

• Eszopiclone 2–3 mg improves both sleep latency and total sleep time in non-elderly adults. 2, 8
• Extended-release zolpidem 6.25–12.5 mg is another option for combined symptoms. 2

Medications to Avoid in Young Adults:

• Benzodiazepines (temazepam, lorazepam, clonazepam) carry risks of dependency, cognitive impairment, and are associated with dementia, serious injury, and fractures even in younger populations. 1, 2, 3
• Over-the-counter antihistamines (diphenhydramine, doxylamine) lack efficacy for insomnia and patients develop tolerance within 3–4 days. 2, 6, 9
• Trazodone provides minimal benefit (≈10 minutes shorter sleep latency) with no improvement in subjective sleep quality, and approximately 75% of patients experience adverse events. 2, 6
• Melatonin supplements do not demonstrate clinically meaningful effects for insomnia treatment. 1, 2, 3

Duration and Monitoring:

• FDA-approved hypnotics are indicated for short-term use (typically 4–5 weeks); prolonged continuous use is discouraged. 1, 3
• Reassess patients every 2–4 weeks initially to assess effectiveness and side effects, employing the lowest effective maintenance dosage. 2

---

Older Adults (≥65 years)

First-Line Treatment: Cognitive Behavioral Therapy for Insomnia (CBT-I)

CBT-I is the gold-standard initial treatment for older adults with chronic insomnia, providing superior long-term outcomes with benefits sustained up to 2 years and no medication-related risks such as falls, cognitive impairment, fractures, or dementia. 1, 2, 6, 3

• CBT-I should be initiated before any hypnotic medication because behavioral interventions provide superior long-term outcomes and reduce polypharmacy risk. 2
• A 1–2-week sleep log is used to calculate mean total sleep time (TST) for individualized time-in-bed (TIB) prescription; prescribed TIB should match calculated TST while maintaining sleep efficiency ≥85%, with TIB never set below 5 hours. 2
• Weekly TIB adjustments: increase by 15–20 minutes if sleep efficiency >85–90%, decrease by 15–20 minutes if <80%. 2
• Stimulus-control instructions, sleep-hygiene modifications, and relaxation techniques are core components. 2, 3

Second-Line Treatment: Pharmacotherapy (Only After CBT-I Failure)

Pharmacotherapy should only be added after CBT-I has failed, and all medications must be started at the lowest available dose in elderly patients due to reduced drug clearance and increased sensitivity to peak effects. 1, 2, 6, 3

For Sleep-Onset Insomnia:

• Ramelteon 8 mg at bedtime is the preferred option, with minimal adverse effects and no dependency risk. 2, 6, 3
• Short-acting Z-drugs (zolpidem 5 mg maximum, zaleplon 5 mg) are alternatives, but FDA recommends lower doses than standard adult dosing. 2, 3

For Sleep-Maintenance Insomnia (Most Common Pattern in Elderly):

• Low-dose doxepin 3–6 mg is the most appropriate medication for sleep-maintenance insomnia in older adults, with demonstrated improvement in Insomnia Severity Index scores, total sleep time, wake after sleep onset, and sleep quality, without the black box warnings or significant safety concerns of other sleep medications. 1, 2, 6, 3
• Start with 3 mg taken 30 minutes before bedtime; if response is inadequate after 1–2 weeks, increase to 6 mg. 2, 6
• Suvorexant 10 mg (not 20 mg) is an alternative for sleep maintenance, with only mild side effects. 2, 6

For Combined Sleep-Onset and Maintenance Insomnia:

• Eszopiclone 1–2 mg (starting at 1 mg) improves both global and sleep outcomes in older adults. 1, 2, 3, 8
• Extended-release zolpidem 6.25 mg is another option. 2

Medications That Must Be Avoided in Older Adults:

The following medications are explicitly contraindicated or strongly discouraged in elderly patients due to unacceptable risk-benefit profiles:

• All benzodiazepines (temazepam, lorazepam, clonazepam, triazolam, flurazepam, quazepam) are contraindicated as first-line agents due to higher risks of falls, cognitive impairment, dependence, respiratory depression, and increased dementia risk (including long-term use at low intermittent doses). 1, 2, 6, 3
• Over-the-counter antihistamines (diphenhydramine, hydroxyzine, chlorpheniramine) should be avoided due to strong anticholinergic effects (confusion, urinary retention, constipation, fall risk, daytime sedation, delirium) and can accelerate cognitive decline. 2, 6, 3
• Trazodone is explicitly not recommended by the American Academy of Sleep Medicine for insomnia in older adults, as it reduces sleep-onset latency by only ≈10 minutes and wake-after-sleep-onset by ≈8 minutes with no improvement in subjective sleep quality, while approximately 75% of older adults experience adverse events (headache ≈30%, somnolence ≈23%). 2, 6, 3
• Sedating antidepressants (amitriptyline, mirtazapine) should only be used when comorbid depression/anxiety exists, as there is no systematic evidence for effectiveness in primary insomnia and risks outweigh benefits. 2, 6
• Barbiturates, chloral hydrate, and herbal supplements (valerian, melatonin) are not recommended due to lack of efficacy and safety data. 2, 6, 3
• Antipsychotics (quetiapine, olanzapine, risperidone) should be avoided due to sparse evidence, small sample sizes, known harms including increased mortality risk in elderly populations with dementia, and QTc prolongation concerns. 6

Critical Safety Considerations for Older Adults:

• Medication review is essential: β-blockers, bronchodilators, corticosteroids, decongestants, diuretics, and SSRIs/SNRIs frequently cause or worsen insomnia in older adults. 2, 3
• Monitor closely for: next-day impairment, falls, confusion, complex sleep behaviors (sleep-driving), cognitive changes, orthostatic hypotension, and respiratory depression. 2, 6, 3
• Screen for comorbid sleep disorders: obstructive sleep apnea, restless-legs syndrome, and REM-behavior disorder can diminish treatment efficacy if untreated. 2
• Combining CBT-I with pharmacotherapy may provide better short-term outcomes than either modality alone, with medications providing rapid onset relief and behavioral therapy providing longer-term sustained benefit; medication tapering and discontinuation are facilitated by concurrent CBT-I. 2, 6

Duration and Monitoring in Older Adults:

• Limit pharmacological therapy to short-term use when possible, typically less than 4 weeks for acute insomnia, with the lowest effective dose for the shortest period. 6, 3
• For patients requiring chronic hypnotic medication due to severe or refractory insomnia, administration may be nightly, intermittent (three nights per week), or as needed, with consistent follow-up and ongoing assessment. 2
• Reassess patients every few weeks initially to assess effectiveness and side effects, and employ the lowest effective maintenance dosage and taper when conditions allow. 2

---

Key Differences Between Young and Older Adults:

Aspect	Young Adults (18–40 years)	Older Adults (≥65 years)
First-line treatment	CBT-I [1,2]	CBT-I [1,2,6,3]
Pharmacologic dosing	Standard adult doses [2]	Start at lowest available dose (e.g., zolpidem 5 mg max, eszopiclone 1 mg start) [1,2,3]
Preferred medication for sleep-onset	Ramelteon 8 mg, zolpidem 5–10 mg [2]	Ramelteon 8 mg, zolpidem 5 mg max [2,3]
Preferred medication for sleep-maintenance	Suvorexant 10–20 mg, doxepin 3–6 mg [2,6]	Low-dose doxepin 3–6 mg (first choice), suvorexant 10 mg [2,6,3]
Benzodiazepine use	Avoid due to dependency and cognitive risks [1,2]	Absolutely contraindicated due to falls, dementia, fractures [1,2,6,3]
Antihistamine use	Avoid due to tolerance and lack of efficacy [2,6]	Absolutely contraindicated due to anticholinergic effects and cognitive decline [2,6,3]
Trazodone use	Not recommended [2,6]	Explicitly contraindicated by AASM [2,6,3]
Safety monitoring	Standard adverse-event monitoring [2]	Intensive monitoring for falls, confusion, next-day impairment, orthostatic hypotension [2,6,3]

---

Common Pitfalls to Avoid:

• Prescribing hypnotic medication before attempting CBT-I, which forfeits the more durable benefits of behavioral therapy. 2
• Using standard adult dosing in older adults; age-adjusted dosing is essential to reduce fall and cognitive-impairment risk. 2, 3
• Assuming sleep hygiene education alone will suffice, as it must be combined with other CBT-I modalities for chronic insomnia. 2, 4
• Overlooking medication-induced insomnia (β-blockers, diuretics, SSRIs) as a common and often missed cause in older adults. 2, 3
• Prescribing benzodiazepines or antihistamines in older adults despite explicit guideline recommendations against their use. 1, 2, 6, 3
• Failing to screen for comorbid sleep disorders (sleep apnea, restless-legs syndrome) that can undermine insomnia treatment. 2